SCHEMBL2921168

SCHEMBL2921168

Cc1ccc(C2CCN(C(=O)Oc3ccc4cc(CN5CCCC5)ccc4c3)CC2)cc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MCHR1 Q99705 5/20 0.54
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
HTT P42858 1/20 0.47
FAAH O00519 4/20 0.47
HRH3 Q9Y5N1 2/20 0.47
LSS P48449 1/20 0.46
NPC1 O15118 1/20 0.44
LMNA P02545 1/20 0.44
RAB9A P51151 1/20 0.44
ATM Q13315 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HTR2C P28335 1/20 0.44
DRD2 P14416 2/20 0.43
DRD4 P21917 2/20 0.43
DRD3 P35462 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2927611 0.92 MCHR1 (0.59) MCHR1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2927249 0.90 LSS (0.56) MCHR1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL2928091 0.90 FAAH (0.59) MCHR1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL13177246 0.90 MCHR1 (0.53) MCHR1MAPTSMN1; SMN2MEN1KMT2A
Hydrochloric Acid SCHEMBL2925218 0.89 MCHR1 (0.52) MCHR1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6305166 0.81 MCHR1 (0.77) MCHR1MAPTSMN1; SMN2HTTFAAH
SCHEMBL2927911 0.80 MCHR1 (0.75) MCHR1MAPTSMN1; SMN2HTTFAAH
SCHEMBL6304593 0.76 MCHR1 (0.70) MCHR1MAPTSMN1; SMN2HTTFAAH
SCHEMBL6313616 0.76 MCHR1 (0.69) MCHR1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL6306508 0.76 MCHR1 (0.69) MCHR1MAPTSMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
EP-1285651-B1 MELANIN CONCENTRATING HORMONE ANTAGONISTS TAKEDA PHARMACEUTICAL (JP) 2010-09-01 EP disclosed
US-6930185-B2 Melanin-concentrating hormone antagonist TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2005-08-16 US disclosed
US-20040077628-A1 Melanin-concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-22 US disclosed
EP-1285651-A1 MELANIN CONCENTRATING HORMONE ANTAGONISTS Takeda Chemical Industries, Ltd. (JP) 2003-02-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077628-A1 Melanin-concentrating hormone antagonist MCHR1, MC1R, MCHR2 MCHR1 1/4885MAPT 3638/4885SMN1; SMN2 4079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.